Skip to main content
Journal cover image

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

Publication ,  Journal Article
Akabani, G; Cokgor, I; Coleman, RE; González Trotter, D; Wong, TZ; Friedman, HS; Friedman, AH; Garcia-Turner, A; Herndon, JE; DeLong, D ...
Published in: Int J Radiat Oncol Biol Phys
March 1, 2000

PURPOSE: The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of (131)I-labeled 81C6 monoclonal antibody (MAb) into surgically created resection cavities (SCRCs). METHODS AND MATERIALS: Absorbed doses to the 2-cm-thick shell as measured from the margins of the resection cavity interface were estimated for 42 patients with primary brain tumors. MR images were used to assess the enhanced-rim volume as a function of time after radiolabeled MAb therapy. Biopsy samples were obtained from 15 patients and 1 autopsy. RESULTS: The average absorbed dose [range] to the 2-cm shell region was 32 [3-59] Gy. For the endpoint of minimal time to MR contrast enhancement, the optimal absorbed dose and initial dose-rate were 43 +/- 16 Gy and 0. 41 +/- 0.10 Gy/h, respectively. There was a correlation between the absorbed dose and dose rate to the shell region and biopsy outcome (tumor recurrence, radionecrosis, and tumor recurrence and/or radionecrosis). In this Phase I study, the maximum tolerated dose (MTD) was 120 mCi. At this MTD, the estimated average absorbed dose and initial dose rate to the 2-cm shell were 41 [9-89] Gy and 0.51 [0.24-1.13] Gy/h, respectively. These values are in agreement with the optimal values based on the time to MR lesion rim enhancement. CONCLUSIONS: The average absorbed dose to the 2-cm shell region varied considerably and mainly depended on cavity volume. In future clinical trials, the administered activity of (131)I-labeled 81C6 MAb may be adjusted based on cavity volume in order to deliver the optimal absorbed dose of 43 Gy rather than giving a fixed administered activity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Radiat Oncol Biol Phys

DOI

ISSN

0360-3016

Publication Date

March 1, 2000

Volume

46

Issue

4

Start / End Page

947 / 958

Location

United States

Related Subject Headings

  • Tenascin
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Iodine Radioisotopes
  • Humans
  • Glioma
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Akabani, G., Cokgor, I., Coleman, R. E., González Trotter, D., Wong, T. Z., Friedman, H. S., … Zalutsky, M. R. (2000). Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys, 46(4), 947–958. https://doi.org/10.1016/s0360-3016(99)00500-3
Akabani, G., I. Cokgor, R. E. Coleman, D. González Trotter, T. Z. Wong, H. S. Friedman, A. H. Friedman, et al. “Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.Int J Radiat Oncol Biol Phys 46, no. 4 (March 1, 2000): 947–58. https://doi.org/10.1016/s0360-3016(99)00500-3.
Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947–58.
Akabani, G., et al. “Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.Int J Radiat Oncol Biol Phys, vol. 46, no. 4, Mar. 2000, pp. 947–58. Pubmed, doi:10.1016/s0360-3016(99)00500-3.
Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947–958.
Journal cover image

Published In

Int J Radiat Oncol Biol Phys

DOI

ISSN

0360-3016

Publication Date

March 1, 2000

Volume

46

Issue

4

Start / End Page

947 / 958

Location

United States

Related Subject Headings

  • Tenascin
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Iodine Radioisotopes
  • Humans
  • Glioma
  • Female